FDA Pulls Approval of TAZVERIK Cancer Drug
Published Date: 6/22/2026
Notice
Summary
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 3 costs, 1 mixed.
TAZVERIK approval withdrawn June 22, 2026
The FDA withdrew approval of NDA 211723 for TAZVERIK (tazemetostat) 200 mg tablets effective June 22, 2026. TAZVERIK will no longer be an FDA‑approved treatment for adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, nor for the two follicular lymphoma indications approved June 18, 2020.
Safety signal in confirmatory trial
Epizyme notified FDA on March 6, 2026, of an increased rate of second primary malignancies in the TAZVERIK arm of the SYMPHONY-1 (EZH-302) confirmatory trial. That safety finding was a reason cited for withdrawing approval of the drug.
Insurance and treatment access may change
Because approval was withdrawn as of June 22, 2026, coverage and access to TAZVERIK by insurers or pharmacies may change. If you or someone is being treated with TAZVERIK, check with your doctor and insurer about next steps and coverage options.
Post‑withdrawal sales are illegal
After approval was withdrawn on June 22, 2026, distribution of TAZVERIK 200 mg tablets into interstate commerce without an approved application is illegal and subject to regulatory action under the FD&C Act. Epizyme also withdrew TAZVERIK from marketing in the United States.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
Previous / Next Documents
Previous: 2026-12366 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-Information Warfare Research Project Consortium
The Information Warfare Research Project Consortium just updated its team by adding 26 new members and saying goodbye to 9 others. This change helps protect members from big antitrust lawsuits, limiting damages to actual losses. If you’re part of this tech and defense group, keep an eye out for more updates as membership stays open and active.
Next: 2026-12368 — Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Form 3-Initial Statement of Beneficial Ownership of Securities
The SEC is asking to keep using Form 3, which insiders fill out to report when they own more than 10% of a company’s stock. They want to extend approval for this form and make it a 'common form' so other agencies, like the Federal Reserve, can use it too. This won’t cost extra money but helps keep insider trading info clear and up to date.